Palvella Therapeutics
PVLA
95 hedge funds and large institutions have $85.9M invested in Palvella Therapeutics in 2020 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 30 increasing their positions, 31 reducing their positions, and 18 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
0.03% more ownership
Funds ownership: 0.81% → 0.84% (+0.03%)
3% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 31
2% less funds holding
Funds holding: 97 → 95 (-2)
11% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 18
33% less capital invested
Capital invested by funds: $129M → $85.9M (-$42.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
Corriente Advisors
Fort Worth,
Texas
|
+$5.61M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$3.29M |
| 3 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$2.89M |
| 4 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$1.92M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
+$1.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$7.15M |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$1.3M |
| 3 |
Morgan Stanley
New York
|
-$1.29M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$719K |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$701K |
PVLA Hedge Fund Activity: Q1 2020 in Review
95 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q1 2020, worth a combined $85.9M — down 33% from $129M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of PVLA and 16 opened new positions — a net loss of 2 holders — while 31 trimmed existing stakes and 30 added.
The largest buyer was Corriente Advisors, opening a new position worth an estimated $5.61M. The largest seller was EcoR1 Capital, cutting an estimated $7.15M.
- 95 institutional investors held Palvella Therapeutics (PVLA) as of Q1 2020, down from 97 in Q4 2019.
- Funds reported $85.9M of Palvella Therapeutics stock for Q1 2020, down 33% quarter-over-quarter.
- 16 funds opened new Palvella Therapeutics positions in Q1 2020 and 18 closed out, a net change of -2 holders.
- The largest Palvella Therapeutics buyer in Q1 2020 was Corriente Advisors, an estimated $5.61M added.
- The largest Palvella Therapeutics seller in Q1 2020 was EcoR1 Capital, an estimated $7.15M sold.
Based on aggregated 13F filings for Q1 2020.